Here we tested tozasertib (VX680, MK-0457), a pan aurora kinase inhibitor [16], and alisertib, a second generation aurora kinase inhibitor that inhibits aurora kinase A and B with a higher affinity to aurora kinase A [17], in a panel of drug-resistant neuroblastoma cell lines. The gene discussed is AURKA; the disease is neuroblastoma.